Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

January 15, 2027

Study Completion Date

December 15, 2027

Conditions

SCLC, Extensive Stage

Interventions

DRUG

Nanocrystalline Megestrol Acetate

Nanocrystalline Megestrol Acetate + Tislelizumab+ Chemotherapy (Carboplatin + Etoposide)

DRUG

Tislelizumab

Tislelizumab combined with chemotherapy (Carboplatin + Etoposide)

DRUG

PTOC

Nanocrystalline Megestrol Acetate+PD-(L)1 inhibitors+chemotherapy

Trial Locations (4)

Xinxiang Central Hospital, Xinxiang

Henan cancer hospital,, Zhengzhou

"Zhengzhou Third People's Hospital", Zhengzhou

The First Affiliated Hospital of Henan University of Science and Technolog, Luoyang

All Listed Sponsors

lead

Henan Cancer Hospital

OTHER_GOV

NCT06793228 - Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia | Biotech Hunter | Biotech Hunter